Press releases
September 8, 2021
Eirion Therapeutics Announces Strategic Agreement
As part of the agreement, HTL will build, validate and operate a botulinum manufacturing facility in the US. In the future, HTL Biotechnology expects to apply to the CDC to have the facility certified to manufacture botulinum and later apply to the FDA to have it certified as a GMP plant.
Read more below.
To see our most recent news,
Read more
news from us
-
Articles April 16, 2024HTL Biotechnology at In-cosmetics Global Congress in Paris
As every year, the In-Cosmetics Global Congress returns to Paris, with top industry leaders and experts gathering under one roof.
This event promises opportunities and insights into the future of Cosmetics. -
Articles April 9, 2024France BioLead Membership
France BioLead structures, pilots, supports and promotes the French biomanufacturing sector.
-
Articles March 28, 2024Attending AMWC in Monaco
AMWC, the Aesthetic & Anti-Aging Medicine World Congress in Monaco.